Delta COVID Variant Becoming Globally Dominant, Says Top WHO Scientist
WHO officials said Africa remains an area of concern, even though it accounts for only around 5% of new global infections and 2% of deaths.
The Delta variant of COVID-19, first identified in India, is becoming the globally dominant variant of the disease, the World Health Organization's chief scientist said on Friday.
Soumya Swaminathan also voiced disappointment in the failure of CureVac's vaccine candidate in a trial to meet the WHO's efficacy standard, in particular as highly transmissible variants boost the need for new, effective shots.
Britain has reported a steep rise in infections with the Delta variant, while Germany's top public health official predicted it would rapidly become the dominant variant there despite rising vaccination rates.
The Kremlin blamed a surge in COVID-19 cases on reluctance to have vaccinations and "nihilism" after record new infections in Moscow, mostly with the new Delta variant, fanned fears of a third wave.
"The Delta variant is well on its way to becoming the dominant variant globally because of its increased transmissibility," Swaminathan told a news conference.
Coronavirus variants were cited by CureVac when the German company this week reported its vaccine proved only 47% effective at preventing disease, shy of the WHO's 50% benchmark.
The company said it documented at least 13 variants circulating within its study population.
Given that similar mRNA vaccines from Pfizer and BioNTech and Moderna posted efficacy rates topping 90%, Swaminathan said the world had been expecting more from CureVac's candidate.
"Just because it's another mRNA vaccine, we cannot presume all mRNA vaccines are the same, because each one has a slightly different technology," Swaminathan said, adding the surprise failure underscored the value of robust clinical trials to test new products.
WHO officials said Africa remains an area of concern, even though it accounts for only around 5% of new global infections and 2% of deaths.
New cases in Namibia, Sierra Leone, Liberia and Rwanda have doubled in the last week, WHO emergencies programme head Mike Ryan said, while vaccine access remains miniscule.
"It's a trajectory that is very, very concerning," Ryan said. "The brutal reality is that in an era of multiple variants, with increased transmissibility, we have left vast swathes of the population, the vulnerable population of Africa, unprotected by vaccines."
Soumya Swaminathan also voiced disappointment in the failure of CureVac's vaccine candidate in a trial to meet the WHO's efficacy standard, in particular as highly transmissible variants boost the need for new, effective shots.
Britain has reported a steep rise in infections with the Delta variant, while Germany's top public health official predicted it would rapidly become the dominant variant there despite rising vaccination rates.
The Kremlin blamed a surge in COVID-19 cases on reluctance to have vaccinations and "nihilism" after record new infections in Moscow, mostly with the new Delta variant, fanned fears of a third wave.
"The Delta variant is well on its way to becoming the dominant variant globally because of its increased transmissibility," Swaminathan told a news conference.
Coronavirus variants were cited by CureVac when the German company this week reported its vaccine proved only 47% effective at preventing disease, shy of the WHO's 50% benchmark.
The company said it documented at least 13 variants circulating within its study population.
Given that similar mRNA vaccines from Pfizer and BioNTech and Moderna posted efficacy rates topping 90%, Swaminathan said the world had been expecting more from CureVac's candidate.
"Just because it's another mRNA vaccine, we cannot presume all mRNA vaccines are the same, because each one has a slightly different technology," Swaminathan said, adding the surprise failure underscored the value of robust clinical trials to test new products.
WHO officials said Africa remains an area of concern, even though it accounts for only around 5% of new global infections and 2% of deaths.
New cases in Namibia, Sierra Leone, Liberia and Rwanda have doubled in the last week, WHO emergencies programme head Mike Ryan said, while vaccine access remains miniscule.
"It's a trajectory that is very, very concerning," Ryan said. "The brutal reality is that in an era of multiple variants, with increased transmissibility, we have left vast swathes of the population, the vulnerable population of Africa, unprotected by vaccines."
AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.
